Moberg Pharma, a Swedish pharmaceutical company, has announced the completion of patient enrolment in the ongoing Phase II trial of MOB-015.
A topical formulation of terbinafine, MOB-015 has been developed for the treatment of onychomycosis (nail fungus) and has fungicidal and keratolytic properties to remove dead cells from the skin's outermost layer.
Moberg Pharma CEO Peter Wolpert said; "MOB-015 has the potential to become a valuable addition to our product portfolio and we look forward to the outcome of the study during next year."
The study is designed to confirm the product concept of MOB-015, as well as provide a basis for a Phase III study and out-licensing.
Patients will be treated for twelve months and later observed for a total of fifteen months, as per the normally accepted FDA and EMA endpoints for nail fungus.
The Phase II study is being conducted at Sahlgrenska University Hospital in Gothenburg, Sweden.